CRV Closes $750M CRV XX, Refocuses on Early Stage
CRV closed its twentieth flagship fund, CRV XX, at $750M in four weeks, doubling down on early-stage investing and stepping back from late-stage Select funds.
Venture Capital News, Guides & Fund Directory
Venture capital fuels the companies that reshape industries — from AI infrastructure and fintech to healthcare and defense tech. This hub collects our latest analysis on how VC firms evaluate startups, structure deals, and deploy capital across stages and geographies.
What You'll Find Here
- Fund profiles & directories: Stage focus, sector thesis, and check-size context for active investors
- Deal flow analysis: Funding roundups, mega-rounds, and emerging-manager activity
- Founder playbooks: Pitch decks, term sheets, warm intros, and fundraising strategy
- Market intelligence: Sector trends, valuation shifts, and LP allocation patterns
Browse the articles below to research investors, understand deal dynamics, and build a sharper fundraising strategy.
Related Articles (326 articles)
July 2025 NYC VC Fund Roundup: Boldstart $250M, Betaworks $66M, and 49 Global Fund Closes
July 2025 brought Boldstart's $250M Fund VII, Betaworks' $66M AI fund, and Verified Capital's $175M debut — plus $6.77B in global new VC dry powder.
July 2025 Life Sciences Mega Close: Frazier Life Sciences Closes $1.3B Fund XII
Frazier Life Sciences closed Fund XII at over $1.3 billion on July 31, 2025 — one of the largest biotech venture funds closed in July 2025.
July 2025 Growth Equity Close: Glade Brook Raises $515M Fund IV
Greenwich and Miami-based Glade Brook Capital closed Strategic Growth Fund IV at $515 million on July 22, 2025, targeting FinTech, AI, SpaceTech, and DefenseTech growth equity.
NYC VC Fund Launch: Betaworks Closes $66M Fund III for Early-Stage AI
New York City-based Betaworks announced the $66M close of Fund III on July 22, 2025, continuing its legacy of backing creative technologists building AI-native products.
July 2025 VC Fund Close: Modi Ventures Closes $88M Fund II for Tech-Bio Convergence
Houston-based Modi Ventures closed its oversubscribed second fund at $88 million on July 16, 2025, investing at the intersection of AI, biology, and medical technology.